WHO will test 3 potential drugs for new crowns
International war "epidemic" operation
Science and Technology Daily, Beijing, August 12 (Intern reporter Zhang Jiaxin) According to the news from the US "Capitol Hill" on the 11th local time, the WHO stated at the COVID-19 routine press conference held on the same day that it was tested as a "Unity Test +" In part, the WHO will conduct a clinical trial in 52 countries or regions to study three anti-inflammatory drugs as potential treatments for new coronary pneumonia.
The three anti-inflammatory drugs are artesunate, imatinib and infliximab.
"These therapies... were selected by an independent panel of experts because they may reduce the risk of death in hospitalized patients with new coronary pneumonia," the WHO said in a press release.
It is reported that artesunate is produced by Ipuka Laboratories in India for the treatment of malaria.
In the trial, it will be used for intravenous injection for 7 days and is recommended to use the standard dose for the treatment of severe malaria.
Imatinib produced by Novartis of Switzerland is used to treat certain cancers.
In the trial, it will be used orally once a day for 14 days.
Infliximab is produced by Johnson & Johnson and is used to treat immune system diseases such as Crohn's disease and rheumatoid arthritis.
In the trial, it will be administered intravenously as a single dose.
The WHO’s “Solidarity Trial” project last year involved fewer countries and identified all 4 treatments being evaluated-remdesivir, hydroxychloroquine, lopinavir/ritonavir, and interferon seem to be effective in hospitalization. The patient’s 28-day mortality rate or the duration of hospitalization of the new crown patient has little or no impact.
So far, only corticosteroids have been shown to be effective against severe and critical new coronary pneumonia.
Researchers from more than 600 hospitals in 52 countries or regions will participate in this study, which the WHO calls "unprecedented global cooperation for new coronary pneumonia."